RPL17 and head and neck squamous cell carcinoma: The PD1 inhibitors pembrolizumab and nivolumab are currently approved for HNSCC therapy, and the PD-L1 inhibitors durvalumab, atezolizumab and avelumab are under evaluation in HNSCC 48.